Inventor · disambiguated record
Linda Gillian Durrant
Also filed as: DURRANT LINDA · DURRANT LINDA G · DURRANT LINDA GILLIAN
13 granted patents·14 pending applications·35 citations·filing 1994–2022
88Inventor score
Files withSCANCELL LTD15CEPHALON AUSTRALIA PTY LTD3DURRANT LINDA GILLIAN3ATGEN CO LTD1CANCER RES CAMPAIGN TECH1
Top patents by PatentIndex Score
27 records- 0186US7915387B2Monoclonal antibody Sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agentCEPHALON AUSTRALIA PTY LTD·Filed 2005·Granted Mar 29, 2011·11 cites·8 claims
- 0285US10233220B2Anti-tumour response to modified self-epitopesSCANCELL LTD·Filed 2015·Granted Mar 19, 2019·4 cites·10 claims
- 0383US7267821B2Binding member which binds to both Lewisy and Lewisb haptens, and its use for treating cancerSCANCELL LTD·Filed 2002·Granted Sep 11, 2007·9 cites·7 claims
- 0478US7879983B2Binding member which binds to both Lewis-y and Lewis-b haptens, and its use for treating cancerCEPHALON AUSTRALIA PTY LTD·Filed 2009·Granted Feb 1, 2011·2 cites·5 claims
- 0576US12258377B2Anti-tumour response to modified self-epitopesSCANCELL LTD·Filed 2022·Granted Mar 25, 2025·0 cites·12 claims
- 0672US8742088B2Nucleic acids encoding antibodies or portions thereof comprising a heterologous T cell epitope and their use in modulating T cell responsesDURRANT LINDA GILLIAN·Filed 2009·Granted Jun 3, 2014·4 cites·51 claims
- 0767US2021198334A1Anti-Tumour Response to Modified Self-EpitopesSCANCELL LTD·Filed 2020·Application pending·0 cites
- 0866US10695438B2Anti-tumour immune responses to modified self-epitopesSCANCELL LTD·Filed 2016·Granted Jun 30, 2020·1 cites·14 claims
- 0962US2018346537A1Anti-tumour response to modified self-epitopesSCANCELL LTD·Filed 2018·Application pending·0 cites
- 1061US2008260735A1Transfer request (37 CFR 1.821(e)) humanised antibodies to the epidermal growth factor receptorATGEN CO LTD·Filed 2008·Application pending·0 cites
- 1161US2008085278A1Binding member which binds to both lewis-y and lewis-b haptens, and its use for treating cancerSCANCELL LTD·Filed 2007·Application pending·0 cites
- 1259US8187600B2Polypeptides capable of binding to CD64 comprising one or more heterologous T cell epitopes and their usesDURRANT LINDA GILLIAN·Filed 2010·Granted May 29, 2012·1 cites·18 claims
- 1357US2006240003A1Humanised antibodies to the epidermal growth factor receptorSCANCELL LTD·Filed 2006·Application pending·0 cites
- 1455US2010040620A1ANTI-CANCER ANTIBODIES AGAINST LEWISy AND LEWISb ANTIGENSDURRANT LINDA GILLIAN·Filed 2007·Application pending·0 cites
- 1554US8273349B2Binding member which binds to both lewis-Y and lewis-B haptens, and its use for treating cancerDURRANT LINDA·Filed 2010·Granted Sep 25, 2012·0 cites·15 claims
- 1653US2004091485A1Humanised antibodies to the epidermal growth factor receptorFiled 2001·Application pending·0 cites
- 1752US11382985B2Anti-tumour immune responses to modified self-epitopesSCANCELL LTD·Filed 2020·Granted Jul 12, 2022·0 cites·14 claims
- 1852US2005095253A1Tumour associated antigen 791Tgp72Filed 2004·Application pending·0 cites
- 1951US2023173047A1Citrullinated nucleophosmin peptides as cancer vaccinesSCANCELL LTD·Filed 2021·Application pending·0 cites
- 2050US8343490B2Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agentCEPHALON AUSTRALIA PTY LTD·Filed 2011·Granted Jan 1, 2013·0 cites·6 claims
- 2150US2025269000A1Anti-tumour responses to cytokeratinsSCANCELL LTD·Filed 2021·Application pending·0 cites
- 2249US2022324997A1Ssea-4 binding membersSCANCELL LTD·Filed 2020·Application pending·0 cites
- 2348US2023310584A1Nucleic acids encoding a polypeptide comprising a modified fc region of a human igg1 and at least one heterologous antigenSCANCELL LTD·Filed 2021·Application pending·0 cites
- 2446US12458688B2EpitopesSCANCELL LTD·Filed 2019·Granted Nov 4, 2025·0 cites·8 claims
- 2544US2022267465A1Binding membersSCANCELL LTD·Filed 2020·Application pending·0 cites
- 2636US2004146505A1SubstancesFiled 2002·Application pending·0 cites
- 2728US6042827AAnti-idiotypic antibody induction of anti-tumor responseCANCER RES CAMPAIGN TECH·Filed 1994·Granted Mar 28, 2000·3 cites·5 claims
Join the waitlist — get patent alerts
Get an alert when Linda Gillian Durrant files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →